Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs and does not recommend treatment solutions (if involved), nor does it represent the platform's position.Any article reprinted needs to be authorized.
4Month29Day, Focused on Revolutionary In Vivo (in vivo）CAR-TIVACTA Biotechnology AnnouncesRecently completed in successionAWheel andA+Round of financing, total financing scale exceeds5000Million USD. The two rounds of financing were led by Zhenxin Capital and Decheng Capital, respectively,OrbiMed(OrbiMed), H&Q Healthcare Fund, Eisai Innovation Venture Fund (Eisai Innovation Inc.), C&D Emerging Investment, and existing shareholders Qiming Venture Partners, Shunxi Fund, Apricot Capital, among other well-known investment institutions, also participated in the investment.The latest financing will be mainly used for IVACTA Biotechnology.Core ProductGT801The clinical trial progress and registration submission work, as well as the expansion of the research and development team and platform construction, are accelerating IVACTA Biotechnology's progress in vivo.CAR-TGlobal Layout in the Field of Therapy.
Notably, within less than half a year, IVACTA Biotechnology has completed three rounds of financing, including angel funding, Series A, and Series A+ rounds.The financing amount exceeds 400 million RMB.The successive completion of multiple rounds of financing, as well as the recognition from global industry capital and biotechnology professional investors, fully demonstrates the development potential of IVACTA Biotechnology's innovative in vivo CAR-T technology.IVACTA Biotechnology was founded in June 2025, spun off from Beijing Gracell Biomedicines Co., Ltd., which separated its leading in vivo CAR-T technology platform. As an emerging force in the global in vivo cell therapy field, IVACTA Biotechnology focuses on the development of in vivo CAR-T therapies based on targeted lipid nanoparticle (LNP) delivery systems, aiming to provide breakthrough treatments for hematologic malignancies and autoimmune diseases.
IVACTA Biotechnology's core pipeline GT801 has entered clinical trials and is currently undergoing an investigator-initiated trial (IIT study).GT801 is an innovative anti-CD19 in vivo CAR product that delivers optimized mRNA through T cell-targeting LNPs. This platform integrates the CLAMP technology co-developed by Grail Bio and IVACTA Biotechnology, enabling the precise and quantitative conjugation of T cell-targeting VHH antibodies with LNPs. This approach enhances targeting efficiency while avoiding non-specific uptake, promoting specific and efficient CAR expression and maximizing the functionality of in vivo generated CAR-T cells.
IVACTA Biotechnology's In Vivo CAR-T Technology Route
GT801 aims to directly generate potent and long-lasting CAR-T cells within patients, supporting repeated dosing to achieve a low-cost, highly effective, and easy-to-use clinical solution, breaking through the commercial bottleneck of high cost and long cycle associated with ex vivo cell manufacturing processes.In December 2025, IVACTA Biotechnology presented the preliminary human data from the GT801 project IIT study in an oral presentation at ASH 2025. The data showed:The clinical manifestations showed good overall tolerance, with high CAR expression levels in peripheral blood T cells. Persistent and reproducible CAR-T expansion was observed after each administration. No CAR expression was detected in peripheral blood mononuclear cells, indicating that GT801 has no off-target delivery risk. This confirms that the T-LNP delivery platform can fully enhance targeting efficiency while avoiding non-specific uptake.GT801 Exhibits Rapid and Efficient Pharmacokinetics, Quickly Depleting B Cells in Peripheral Blood and Various Tissues; Bone Marrow and Lymph Node Biopsies of Two Patients Show Effective B Cell Clearance. By the Fourth Week After Multiple Dosing, the First Two Non-Hodgkin Lymphoma Patients Achieved Partial Remission.References:
Company Website
Mastering CAR-T Therapy, Stem Cell Therapy, GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
